Dystonia: An update on genetics and treatment

Current Opinion in Neurology

Volumn 14, Issue 4, 2001, Pages 471-475

  Misbahuddin, Anjum ^a   Warner, Thomas T ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN B; CHOLINERGIC RECEPTOR BLOCKING AGENT;

BRAIN DEPTH STIMULATION; DENERVATION; DYSTONIA; GENE LOCUS; GENETICS; GLOBUS PALLIDUS; MOLECULAR CLONING; PHENOTYPE; REVIEW;

ADULT; BOTULINUM TOXIN TYPE A; CARRIER PROTEINS; CHILD; CHROMOSOME MAPPING; COMBINED MODALITY THERAPY; DYSTONIA; HUMANS; LEVODOPA; MOLECULAR CHAPERONES; PHENOTYPE;

EID: 0034904845     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200108000-00007     Document Type: Review

References (46)

1. Classification of dystonia
2. Epidemiology of focal and generalised dystonia in Rochester
3. A prevalence study of primary dystonia in eight European countries
4. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein
5. Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population
6. The DYT1 phenotype and guidelines for diagnostic testing
7. Detailed haplotype analysis in Ashkenazi Jewish and non-Jewish British dystonic patients carrying the GAG deletion in the DYT1 gene: Evidence for a limited number of founder mutations
8. Expression of the early onset torsion dystonia gene (DYT1) in the human brain
9. Striatal dopamine in early-onset primary torsion dystonia with the DYT1 mutation
10. Immunohistochemical localization and distribution of torsinA in normal human and rat brain
11. +: A class of chaperone-like ATPases associated with the assembly, operation, and disassembly of protein complexes
12. Mutant torsinA, responsible for early-onset torsion dystonia, forms membrane inclusions in cultured neural cells
13. TorsinA and its torsion dystonia-associated mutant forms are lumenal glycoproteins that exhibit distinct subcellular localizations
14. Dystonia in Ashkenazi Jews: Clinical characterization of a founder mutation
15. The role of DYT1 in primary torsion dystonia in Europe
16. Phenotypic expression of the DYT1 mutation: A family with writer's cramp of juvenile onset
17. Idiopathic torsion dystonia linked to chromosome 8 in two Mennonite families
18. DYT13, a novel primary torsion dystonia locus, maps to chromosome 1p36. 13-36.32 in an Italian family with cranial - Cervical or upper limb onset
19. Primary torsion dystonia: The search for genes is not over
20. Idiopathic torsion dystonia: Assignment of a gene to chromosome 18p in a German family with adult onset, autosomal dominant inheritance and purely focal distribution
21. Sporadic focal dystonia in northwest Germany: Molecular basis on chromosome 18p
22. Search for a founder mutation in idiopathic focal dystonia from Northern Germany
23. Dopa-responsive dystonia: Recent advances and remaining issues to be addressed
24. Hereditary progressive dystonia with marked diurnal variation caused by mutations in the GTP cyclohydrolase I gene
25. Levodopa-Responsive dystonia: Gtp cyclohydrolaseI or parkin mutations?
26. A point mutation in the tyrosine hydroxylase gene associated with Segawa's syndrome
27. Dopa-responsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase gene mutations
28. Association of a missense change in the D2 dopamine receptor with myoclonus dystonia
29. Localization of a gene for myoclonus - Dystonia to chromosome 7q21-q31
30. Inherited myoclonus - Dystonia syndrome: Narrowing the 7q21-q31 locus in German families
31. Dystonia
32. Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia
33. Resistance to botulinum toxin injections for spasmodic dysphonia
34. The sternocleidomastoid test: An in vivo assay to investigate botulinum toxin antibody formation in humans
35. Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance
36. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia
37. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia
38. Outcome of selective ramisectomy for botulinum toxin resistant torticollis
39. Symptomatic and functional outcome of surgical treatment of cervical dystonia
40. Pattern of premature degenerative changes of the cervical spine in patients with spasmodic torticollis and the impact on the outcome of selective peripheral denervation
41. Thalamic, pallidal, or subthalamic surgery for Parkinson's Disease
42. Treatment of DYT1-generalised dystonia by stimulation of the internal globus pallidus
43. Pallidal stimulation for generalized dystonia
44. Globus pallidus deep brain stimulation for generalized dystonia: Clinical and PET investigation
45. Bilateral stimulation of globus pallidus internus for treatment of cervical dystonia
46. Bilateral pallidal stimulation for cervical dystonia: Dissociated pain and motor improvement